KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Accured Expenses (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Change in Accured Expenses for 18 consecutive years, with $107.7 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Accured Expenses rose 150.3% year-over-year to $107.7 million; the TTM value through Mar 2026 reached $1.1 billion, up 157.88%, while the annual FY2025 figure was $736.8 million, 0.23% changed from the prior year.
  • Change in Accured Expenses hit $107.7 million in Q1 2026 for Regeneron Pharmaceuticals, up from -$24.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $759.2 million in Q3 2025 and bottomed at -$250.4 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $120.0 million, with a median of $110.5 million recorded in 2024.
  • Year-over-year, Change in Accured Expenses plummeted 621.61% in 2022 and then skyrocketed 460.95% in 2023.
  • Regeneron Pharmaceuticals' Change in Accured Expenses stood at $347.6 million in 2022, then plummeted by 139.9% to -$138.7 million in 2023, then soared by 262.65% to $225.6 million in 2024, then plummeted by 110.95% to -$24.7 million in 2025, then skyrocketed by 536.03% to $107.7 million in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $107.7 million, -$24.7 million, and $759.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.